You are here: Industry Insights > lung cancer

News List

FDA Approves First Adjuvant Therapy for Most Common Type of Lung Cancer americanpharmaceuticalreview
December 23, 2020
The U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.
Green light for AZ’s Tagrisso in early-stage lung cancer pharmatimes
December 22, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) for the treatment of adult patient with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
EU to review Merck's targeted lung cancer drug pharmatimes
November 30, 2020
European regulators will review Merck's tepotinib for a specific type of lung cancer, having validated the drug's marketing application.
EMA validates Merck’s application to review tepotinib for lung cancer pharmaceutical-technology
November 30, 2020
The European Medicines Agency (EMA) has validated Merck’s application for reviewing tepotinib as a treatment for adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 ...
AZ’s Tagrisso scores priority review from FDA pharmatimes
October 22, 2020
AstraZeneca’s EGFR-tyrosine kinase inhibitor Tagrisso has been granted a priority review by the US Food and Drug Administration (FDA) for the treatment of early-stage EGFR-mutated lung cancer.
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs prnasia
October 14, 2020
A recent study published in JAMA Network Open has shown that an AI algorithm trained to detect pulmonary nodules can improve lung cancer detection on chest radiographs.
FDA Approves Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer drugs.com
September 23, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection ...
BMS' Opdivo wins new NICE lung cancer backing pharmatimes
September 21, 2020
NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer (NSCLC).
TAGRISSO granted FDA breakthrough therapy status in EGFR-mutated lung cancer pharmaceutical-business-review
August 05, 2020
AstraZeneca’s TAGRISSO (osimertinib) has been granted Breakthrough Therapy Designation (BTD) in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer...
First Patient Enrolled in Pafolacianine Sodium Trial for Lung Cancer Lesions americanpharmaceuticalreview
July 20, 2020
On Target Laboratories has enrolled the first patient in the ELUCIDATE Trial, a Phase 3 clinical trial evaluating the efficacy and safety of pafolacianine sodium (formerly OTL38) in the intraoperative detection of lung cancer lesions.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page